ISRCTN85479564进行中（未招募）未知
Burden of hereditary angioedema (HAE) and impact on quality of life: a multi-national survey of patients and caregivers
Takeda (Switzerland)0 个研究点目标入组 750 人开始时间: 2022年10月31日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 750
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 性别
- All
入选标准
- •1. Self-reported diagnosis of HAE (Types I, II, normal functioning C1-INH, or unknown type)
- •2. Age 18 years or older
- •3. Experienced at least 1 episode of angioedema or prodromal symptoms within the last year
- •4. Has been treated with a prescription medication for an angioedema attack within the last 2 years
- •5. Able to understand and provide consent
- •6. Willing to complete an web-based survey
- •7. Adequate fluency in the target language in which the survey is designed:
- •7.1. Spanish (Argentina & Colombia)
- •7.2. Brazilian Portuguese (Brazil)
- •7.3. Croatian (Croatia)
- •7.4. Danish (Denmark)
- •7.5. Hungarian (Hungary)
- •7.6. English (Ireland)
- •7.7. Norwegian (Norway)
- •7.8. Polish (Poland)
- •7.9. Portuguese (Portugal)
- •7.10. Romanian (Romania)
- •7.11. Swedish (Sweden)
排除标准
- •Does not meet inclusion criteria
研究者
相似试验
尚未招募
Unknown
A survey study of HAE patients: mental QoL and treatment preferencesJPRN-UMIN000054086CSL Behring K.K100
已完成
4 期
A Call Center During HAE Attacks (SOS HAE)Hereditary AngioedemaNCT01679912Assistance Publique - Hôpitaux de Paris200
已完成
2 期
A Study of the Safety and Immunogenicity of Repeated rhC1INH AdministrationGenetic DisordersHereditary AngioedemaNCT00851409Pharming Technologies B.V.25
已完成
2 期
Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary AngioedemaAngioneurotic EdemaHereditary AngioedemaNCT00225147Pharming Technologies B.V.77
已完成
3 期
Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary AngioedemaHereditary AngioedemaAngioneurotic EdemaGenetic DisordersNCT00262301Pharming Technologies B.V.75